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A coding variant of the inflammatory bowel disease (IBD) risk gene ATG16L1 has been associated with defective autophagy 
and deregulation of endoplasmic reticulum (ER) function. IL-22 is a barrier protective cytokine by inducing regeneration 
and antimicrobial responses in the intestinal mucosa. We show that ATG16L1 critically orchestrates IL-22 signaling in 
the intestinal epithelium. IL-22 stimulation physiologically leads to transient ER stress and subsequent activation of STI 
NG-dependent type I interferon (IFN-I) signaling, which is augmented in Atg16l1ΔIEC intestinal organoids. IFN-I signals amplify 
epithelial TNF production downstream of IL-22 and contribute to necroptotic cell death. In vivo, IL-22 treatment in Atg16l1ΔIEC 
and Atg16l1ΔIEC/Xbp1ΔIEC mice potentiates endogenous ileal inflammation and causes widespread necroptotic epithelial cell 
death. Therapeutic blockade of IFN-I signaling ameliorates IL-22–induced ileal inflammation in Atg16l1ΔIEC mice. Our data 
demonstrate an unexpected role of ATG16L1 in coordinating the outcome of IL-22 signaling in the intestinal epithelium.
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Introduction
A defective intestinal barrier, impaired host microbial crosstalk, 
and a chronic preponderance of proinflammatory cytokines and 
T cell–mediated immunity are key elements of the formal etiology 
of human inflammatory bowel disease (IBD). Genome-wide asso-
ciation studies have identified a plethora of >200 risk loci predis-
posing to disease manifestation (Jostins et al., 2012) that cluster in 
distinct molecular pathways, including autophagy (Hampe et al., 
2007), ER stress signaling, and innate immune sensing (Franke et 
al., 2010; Jostins et al., 2012). Although there is a strong genetic 
overlap observed between ulcerative colitis (UC) and Crohn’s dis-
ease (CD), variants in autophagy genes only affect CD patients and 
have been associated with Paneth cell defects (Cadwell et al., 2008).
Autophagy is a process allowing the orderly degradation and 
recycling of cellular components. Insufficient ATG16L1-mediated 
autophagy, e.g., by harboring the CD T300A risk allele, renders 
epithelial cells more susceptible to bacteria and virus-induced 
inflammation (Cadwell et al., 2010; Lassen et al., 2014). Autoph-
agy is also closely intertwined to the unfolded protein response 
(UPR), elicited from the endoplasmic reticulum (Adolph et al., 
2013; Deuring et al., 2014; Tschurtschenthaler et al., 2017). The 
importance of this crosstalk has been emphasized by the finding 
that mice, which are double deficient for the UPR transcription 
factor Xbp1 and Atg16l1 in the intestinal epithelium, develop a 
spontaneous transmural and fistulizing ileal inflammation rem-
iniscent of human CD (Adolph et al., 2013).
IL-22 belongs to the family of IL-10 cytokines, is secreted 
from immune cells, including innate lymphoid cells, T cells, and 
neutrophilic granulocytes, and directly targets intestinal epi-
thelial cells (Sonnenberg et al., 2011; Mielke et al., 2013; Zindl 
et al., 2013; Aden et al., 2016). IL-22 contributes to intestinal im-
mune response toward pathogen infection (Zheng et al., 2008; 
Hernández et al., 2015) and epithelial wound healing (Pickert 
et al., 2009), namely via instruction of epithelial proliferation 
and the induction of secreted antimicrobial proteins (Huber et 
al., 2012; Pham et al., 2014; Lindemans et al., 2015). Hence, IL-10 
itself has been described to diminish epithelial ER stress, which 
involves the induction of chaperones (Hasnain et al., 2013, 2014). 
Thus, we hypothesized that IL-22 could beneficially modulate 
cellular function and epithelial homeostasis in situations of de-
fective autophagy or ER stress.
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In this study, we report that the interplay of the UPR and au-
tophagy pathways orchestrate a physiological dichotomy of IL-22 
signaling in the intestinal epithelium. We demonstrate that epi-
thelial IL-22 stimulation leads to release of cytosolic dsDNA and 
a consecutive self-activation of the cGAS–STI NG–IFN-I pathway 
and necroptosis, which is aggravated by autophagy and ER stress 
deficiency. Mechanistically, this process involves induction of 
epithelial TNF and mixed lineage kinase domain-like protein 
(MLKL), a core protein of the necroptosis machinery. We show 
that IL-22 treatment in animals carrying a conditional deletion of 
Atg16l1 in the intestinal epithelium leads to induction of inflam-
mation upon dextran sodium sulfate (DSS) irritant challenge, 
rather than protection. Collectively, our data identify unexpected 
roles of (1) IL-22 in engaging the cGAS–STI NG pathway to pro-
mote a proinflammatory, necroptotic response in intestinal ep-
ithelial cells and of (2) the key autophagy molecule ATG16L1 in 
balancing the fate of such IL-22 signals in the intestine.
Results
The interplay of ATG16L1-mediated autophagy and ER stress 
resolution governs the cellular fate of IL-22 signaling
To investigate the role of ATG16L1-mediated autophagy on IL-22 
signaling, small intestinal organoids of villin (V)-cre+; Atg16l1fl/fl 
(hereafter called Atg16l1ΔIEC) or villin (V)-cre− Atg16l1fl/fl (here-
after called Atg16l1fl/fl) were cultured in the presence of rmIL-22 
(1, 10, and 100 ng/ml).
IL-22 (100 ng/ml) treatment induced cell death in Atg16l1ΔIEC, 
but not in Atg16l1fl/fl organoids (Fig. 1, A–C), and strongly induced 
Tnf and Cxcl1 expression in Atg16l1ΔIEC organoids, consistent with 
the absence of ATG16L1’s function inducing a proinflammatory 
tone (Fig. 1 D; Adolph et al., 2013). IL-22–induced STAT3 signaling 
appeared unaltered between genotypes although induction of the 
STAT3 downstream target Reg3g was increased in Atg16l1ΔIEC cul-
tures (Fig. 1 E). Chronic ER stress in intestinal organoids derived 
from the small intestine of villin (V)-cre+; Xbp1fl/fl (hereafter 
called Xbp1ΔIEC) also rendered cells susceptible to IL-22–induced 
proinflammatory gene expression compared with villin (V)-cre−; 
Xbp1fl/fl (hereafter called Xbp1fl/fl) organoids (Fig. S1 A; Kaser et 
al., 2008). Hence, we studied whether IL-22 is directly involved 
in epithelial ER stress induction under physiological conditions. 
IL-22 induced ER stress in vivo (Fig. S1 B) and in vitro and exac-
erbated ER stress induced by tunicamycin (TM) in HT-29 IECs 
(Fig. S1, C and D) and in C57BL/6 (WT) small intestinal organ-
oids (Fig. S1 E). Intestinal organoids from Atg16l1ΔIEC (Fig. S1 F) 
or intestinal epithelial Caco-2 cells with a CRI SPR/Cas9-guided 
deletion of ATG16L1 (Fig. S1 G) exhibited an increased sensitivity 
to IL-22–induced ER stress as shown by increased XBP1 splicing.
IL-22–dependent amplification of ER stress severely impaired 
epithelial wound healing and induced a proinflammatory pheno-
type in HT-29 IECs (Fig. S2, A–F). IL-22–mediated enhancement of 
chemically induced ER stress was dependent on STAT3 activation 
as pharmacological inhibition using the STAT3 inhibitor S3I-201 
suppressed ER stress induction and reestablished epithelial wound 
healing. ER stress is known to be counterbalanced by autophagy 
(Adolph et al., 2013). Rapamycin, a known inducer of autophagy, 
prevented ER stress-dependent growth inhibition and proin-
flammatory cytokine production (Fig. S2, G and H) after IL-22 
stimulation. Conversely, inhibition of autophagy by bafilomycin 
A1 (BafA) led to impaired wound healing and increased IL-8 se-
cretion in cells treated with IL-22 (Fig. S2 J). To further delineate 
whether increased cell death in Atg16l1ΔIEC intestinal organoids is 
specific to IL-22, we investigated the effect of IL-10. IL-10 induced 
epithelial cell death only in Atg16l1ΔIEC organoids, but to a lesser ex-
tent compared with IL-22, whereas TM induced cell death in both 
genotypes, with significantly higher rates observed in Atg16l1ΔIEC 
compared with Atg16l1fl/fl organoids (Fig. S3, A and B), indicating 
a generally increased sensitivity to ER stress in ATG16L1-deficient 
intestinal epithelial cells. While we cannot fully exclude effects of 
ATG16L1 deficiency on other STAT3-dependent pathways (includ-
ing IL-10), our data show that ATG16L1 and its interaction with ER 
stress responses strongly influences the outcome of IL-22–depen-
dent signaling in intestinal epithelial cells.
ATG16L1 regulates IL-22–mediated transcriptional responses
To analyze the transcriptomal program elicited by IL-22 in the 
absence or presence of ATG16l1, we performed RNA sequencing 
of small intestinal organoids derived from Atg16l1ΔIEC or Atg161fl/fl 
mice. In total, we found 2,908 differentially expressed genes and 
586 (Atg161fl/fl) versus 484 (Atg16l1ΔIEC) uniquely up-regulated and 
794 (Atg16l1fl/fl) versus 490 (Atg16l1ΔIEC) uniquely down-regulated 
genes in response to IL-22 (10 ng/ml for 24 h; Fig. 2 A and Tables 
S1–S6). The top 25 uniquely up- and down-regulated genes showed 
a surprising number of up-regulated transcripts known to play 
a role in innate immunity and anti-viral response and included 
the IFN-I–dependent genes Oas1g, Oas3, Oas1a, and Irf7 (Fig. 2 B). 
We next performed formal gene set enrichment analysis using 
InnateDB (Breuer et al., 2013) to identify specific GO terms (gene 
ontology of biological processes) associated with genotype and 
treatment. In the top 500 regulated transcripts, we demonstrate 
that only in IL-22–treated Atg16l1ΔIEC, but not Atg16l1fl/fl organoids, 
a significant enrichment of up-regulated processes related to in-
nate immunity, herpes simplex infection, and cellular response to 
IFN-β is present in addition to expected pathways (e.g., ER stress 
and NF-κB activation; Fig. 2 C). Using the STR ING (Szklarczyk et 
al., 2015) database, we performed an interaction analysis of all 
genes included in the GO term “innate immune response,” which 
revealed a densely connected network of known IFN-stimulated 
genes (ISG), e.g., Stat1, Ifit1, Irf7, Oas1g, and Oas2 genes (Fig. 2 D). 
Notably, ISG and related processes were not up-regulated in IL-22–
treated Atg16l1fl/fl intestinal organoids (Fig. S3, C and E). In the ab-
sence of IL-22 stimulation, we only detected one ISG (Ifitm3) to be 
significantly up-regulated in Atg16l1ΔIEC compared with Atg16l1fl/fl 
intestinal organoids (Fig. S3, D and F), indicating the absence of an 
IFN-I signature at baseline. Thus, we conclude that the interplay 
of deficient autophagy and IL-22 signaling is characterized by a 
unique IFN-I gene signature in intestinal epithelial cells.
Loss of Atg16l1 potentiates IL-22–induced IFN-I expression via 
STI NG-dependent recognition of cytosolic dsDNA
As cytosolic dsDNA is a strong inducer of ISG, and autophagy is 
required for removal of double-stranded (ds)DNA (Saitoh et al., 
2009; Bartsch et al., 2017), we tested the hypothesis that IL-22 sig-
naling may induce the release of dsDNA into the cytosol, which 
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in turn may evoke the IFN signature. Using intestinal epithelial 
Caco-2 cells with a CRI SPR/Cas9-guided deletion of ATG16L1 
(ATG16L1−/−), we observed a significant increase of nucleoids 
(i.e., cytosolic speckles staining positive for dsDNA; Bartsch et al., 
2017) in response to IL-22 stimulation, which was augmented in 
ATG16L1−/− cells (Fig. 3, A and B). As initiation of IFN-I secretion 
upon cytosolic dsDNA is established by stimulator of IFN genes 
(STI NG), which is encoded by the Tmem173 gene (Barber, 2015), 
we tested whether IL-22–dependent ISG induction is mediated 
via cyclic GMP-AMP synthase (cGAS, necessary for catalyzing 
cGAMP synthesis for STI NG activation)/STI NG. For this pur-
pose, we derived intestinal organoids from Stinggt mice, which 
harbor a single nucleotide variant (T596A) of Tmem173/STI NG 
that functions as a null allele and fails to produce detectable pro-
tein (Sauer et al., 2011). To exclude a role for cytosolic dsRNA as 
the origin of ISG regulation, we derived intestinal organoids from 
Figure 1. IL-22 induces cell death and a proinflammatory signature in Atg16l1-deficient intestinal organoids. (A) Representative FACS plots of PI-stained 
dissociated cells from intestinal organoids (Atg16l1fl/fl, Atg16l1ΔIEC), treated with rmIL-22 (100 ng/ml) for 24 h. (B) Representative pictures of intestinal organoids 
(Atg16l1fl/fl, Atg16l1ΔIEC), treated with rmIL-22 (100 ng/ml) for 24 h, stained with PI. Bars, 200 µm. (C) Flow cytometry assessment of dead cells from intestinal 
organoids (Atg16l1fl/fl, Atg16l1ΔIEC) stimulated with rmIL-22 (1, 10, or 100 ng/ml) for 24 h using PI (n = 3 each). (D) mRNA expression of Tnf, Cxcl1, Atg16l1, and 
Reg3g in small intestinal organoids (Atg16l1fl/fl, Atg16l1ΔIEC) treated with rmIL-22 (1, 10, or 100 ng/ml) for 24 h as assessed by qPCR (n = 4 each). (E) Western 
blot analysis from intestinal organoids (Atg16l1fl/fl, Atg16l1ΔIEC) treated with rmIL-22 (100 ng/ml) for 30 min, probed against pSTAT3 and GAP DH. Illustrated 
are representative data of three independent experiments. Significance determined using Mann-Whitney test and expressed as the mean ± SEM. **, P < 0.01; 
***, P < 0.001.
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Mda5−/− (melanoma differentiation-associated protein 5) mice, 
which carry a deletion of a crucial dsRNA helicase enzyme nec-
essary for recognition of dsRNA (Wu et al., 2013). We showed that 
IL-22–induced ISG levels are indeed evoked by sensing of dsDNA, 
not RNA, as IL-22–induced ISG expression was completely ab-
rogated in Stinggt, but not Mda5−/− organoids (Fig. 3 C). The de-
pendency of IL-22–initiated ISG induction on the cGAS–STI NG 
pathway was further confirmed using Cgas−/− and Irf3−/− (IFN 
regulatory factor 3, transcription factor downstream of STI NG) 
intestinal organoids, both of which showed absent ISG induc-
tion in response to IL-22 (Fig. 3 D). We excluded an amplifying 
role of type III IFNs for the induction of ISGs, as Il28r−/− organ-
Figure 2. Atg16l1 orchestrates an IL-22–dependent IFN-I signature in intestinal organoids. (A) Venn diagram showing numbers of differentially expressed 
transcripts (overall, black) and significantly up-regulated (below, red) and down-regulated (below, blue) transcripts in small intestinal organoids (Atg16l1fl/fl, 
Atg16l1ΔIEC) in response to stimulation with IL-22 (10 ng/ml) for 24 h (n = 4 each). Differential expression was determined using RNA sequencing and the DES 
EQ2 algorithm. (B) Heat map showing clustering of top 25 up- and down-regulated genes in response to IL-22 (10 ng/ml) according to genotype. (C) Gene set 
enrichment (GO) analysis of top 250 uniquely up-regulated genes in IL-22–treated Atg16l1ΔIEC intestinal organoids. (D) STR ING-based network analysis of all 
genes contributing to the GO term “innate immune response” detected in C. Note a strong contribution of an IFN-I–related signature.
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oids showed an increased ISG expression in response to IL-22 
(Fig. 3 D). IL-22 induced a comparable up-regulation of Sting on 
transcript (Fig. 3 E), as well as protein level (Fig. 3 F), both in 
Atg16l1ΔIEC and Atg16l1fl/fl organoids, indicating that the enhanced 
ISG induction cannot be explained by different Sting levels in the 
absence of ATG16L1. To further investigate whether Atg16l1 defi-
ciency increases downstream signaling of the cGAS–STI NG path-
way, we analyzed the phosphorylation of TANK-binding kinase 
1 (TBK1) in response to IL-22 stimulation, which was stronger in 
Atg16l1ΔIEC organoids (Fig. 3 G) and ATG16L1−/− Caco-2 cells com-
pared with their WT counterparts (Fig. 3 H).
Excessive STI NG activation in Atg16l1ΔIEC organoids was de-
pendent on defective autophagy as pharmacological inhibition of 
autophagy with BafA phenocopied the enhanced IL-22–induced 
ISG induction in WT organoids (Fig. 3 I). We further examined a 
potential interplay of ER stress and IL-22 signaling in amplifying 
epithelial DNA damage and subsequent ISG induction. Epithe-
lial cells cotreated with IL-22 and TM exhibited increased epi-
thelial DNA damage compared with cells treated only with IL-22 
as shown by increased γH2AX staining and increased induction 
of Cxcl10. The latter effect could be rescued by STAT3 inhibition 
(Fig. S2, K and L).
Systemic IL-22 treatment induces intestinal inflammation in 
Atg16l1ΔIEC mice
To investigate the hypothesis that ATG16L1 coordinates protec-
tive IL-22 signaling in vivo, Atg16l1fl/fl and Atg16l1ΔIEC mice were 
treated with daily i.p. injections of recombinant IL-22 (2 µg/20 g 
bodyweight) for 6 d (Fig. 4 A) during a short course (3 d) of DSS 
in drinking water at a low concentration (2%). Atg16l1ΔIEC mice 
presented with increased weight loss and heightened inflamma-
tory disease activity index upon IL-22 treatment (Fig. 4 B). Using 
this mild treatment, we did not observe any induction of colonic 
inflammation, regardless of genotype or treatment (Fig.  4  C). 
Histological analysis revealed that the short course of DSS sur-
prisingly led to significantly increased inflammatory cell infil-
trates into the mucosa of the terminal ileum in Atg16l1ΔIEC mice 
(Fig. 4, D and E), which was markedly enhanced by IL-22 admin-
istration. This was associated with increased levels of epithelial 
cell death and DNA damage as depicted by increased numbers of 
terminal dUTP nick end labeling (TUN EL)+ (Fig. 4, F and G) and 
γH2AX+ epithelial cells (Fig. 4, H and I), when compared with 
littermate Atg16l1fl/fl mice. Of note, Atg16l1ΔIEC mice also at base-
line had slightly higher numbers of TUN EL+ epithelial cells and 
γH2AX+ epithelial cells, which may point to a vulnerable state 
of the epithelial lining in the absence of additional stressors. In 
line with increased STI NG activation, IL-22–treated Atg16l1ΔIEC 
mice displayed a strong increase of punctate pTBK1 staining in 
the small intestinal crypt region (Fig. 4, J and K; and Fig. S4 A) and 
showed epithelial up-regulation of ISG (Ifit1, Ifit3, and Cxcl10) 
and Tnf as demonstrated by quantitative PCR (qPCR; Fig. 4 l).
Systemic IL-22 treatment induces intestinal inflammation in 
Atg16l1ΔIEC/Xbp1ΔIEC mice
We next investigated the impact of IL-22 on the inflammatory 
phenotype in mice carrying an epithelial deletion in Atg16l1 and 
Xbp1 (called Atg16l1ΔIEC/Xbp1ΔIEC mice hereafter; Adolph et al., 
2013). The line is known to develop spontaneous ileitis with signs 
of severe ER stress. Atg16l1fl/fl/Xbp1fl/fl and Atg16l1ΔIEC/Xbp1ΔIEC 
were treated systemically with recombinant IL-22 or PBS for 14 d 
(Fig. 5 A). As expected, Atg16l1ΔIEC/Xbp1ΔIEC presented at baseline 
with significant ileal inflammation and cell death. This pheno-
type was aggravated upon IL-22 stimulation as demonstrated by 
histology (Fig. 5, B and C) and count of TUN EL+ (Fig. 5, D and E) 
and γH2AX+ (Fig. 5, F and G) cells. Intriguingly, IL-22 induced 
an increase in cytosolic dsDNA+ nucleoids (Fig. 5, H and I) and 
consecutive phosphorylation of TBK1+ (Fig. 5, J and K; and Fig. S4 
B) cells along with increased small intestinal Tnf and Ifnb expres-
sion in IL-22–treated Atg16l1ΔIEC/Xbp1ΔIEC mice (Fig. 5 L).
This corroborates the notion that ER stress and autophagy 
pathways control IL-22–dependent activation of STI NG-depen-
dent signaling. Consistent with this, intestinal organoids double 
deficient for Atg16l1 and Ormdl3, another ER stress regulatory 
gene, genetic variants of which confer genetic risk for IBD 
(McGovern et al., 2010), also exhibited significant up-regulation 
of ISG genes and Tnf induction in response to IL-22 stimulation 
(Fig. S4 C). Notably, epithelial ISG and Tnf induction appear con-
fined to IL-22, as other cytokines of the IL-10 family (IL-10 and 
IL-19) were not able to fully phenocopy IL-22 effects in WT intes-
tinal organoids (Fig. S4 D).
cGAS–STI NG licenses TNF production and epithelial 
necroptosis in response to IL-22 stimulation
Increased levels of TNF have been reported in the context of 
impaired ER stress and autophagy (Adolph et al., 2013), and 
TNF-induced cell death in Atg16l1ΔIEC intestinal organoids de-
pends on MLKL, which is a central regulator of necroptosis 
(Matsuzawa-Ishimoto et al., 2017). We therefore investigated 
whether (1) STI NG signaling is involved in epithelial TNF pro-
duction downstream of IL-22 and (2) whether STI NG-ampli-
fied TNF production contributes to cell death in Atg16l1ΔIEC or 
Atg16l1ΔIEC/Xbp1ΔIEC intestinal organoids. We found that TBK1 
phosphorylation upon IL-22 stimulation was increased in 
Atg16l1ΔIEC/Xbp1ΔIEC intestinal organoids suggesting increased 
STI NG activation (Fig. 6 A). IL-22 led to a concentration-depen-
dent up-regulation of Tnf and Mlkl expression (Fig.  6  B). We 
therefore hypothesized that cGAS–STI NG activation in response 
to IL-22 stimulation may orchestrate downstream expression of 
TNF. Supporting this hypothesis, IL-22–induced TNF expression 
(Fig. 6, C and D) was significantly reduced in Stinggt organoids, 
whereas vice versa cotreatment of Stinggt with IL-22 and IFN-β 
significantly increased Tnf and Cxcl10 expression (Fig. 6 E). To 
delineate whether type III IFNs (e.g., IFN-λ) are involved in the 
IL-22 amplification loop to induce TNF, we stimulated intesti-
nal organoids from WT or mice deficient for Il28r, the receptor 
for IFN-λ, with IL-22. IL-22–induced expression of Cxcl10 and 
Tnf were increased in Il28r−/− organoids, indicating that IFN-λ 
is not involved in amplifying Tnf induction (Fig. 6 F), but rather 
dampens inflammatory epithelial responses, as described pre-
viously (Chiriac et al., 2017). The enhancing effect of IL-22 and 
IFN-I on TNF induction was further confirmed in WT organoids 
as costimulation with IL-22, and IFN-β showed significantly in-
creased Tnf and Mlkl gene expression (Fig. 6 G) and increased 
TNF protein concentration (Fig. 6 H).
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Figure 3. ATG16L1 coordinates an IL-22–dependent IFN-I signature via STI NG signaling. (A and B) Representative pictures (A) and quantification (B) of 
dsDNA in Caco-2 cells (ATG16L1+/+ vs. ATG16L1−/−) treated with rhIL-22 (100 ng/ml) for 24 h (n = 3 each). dsDNA was visualized in Caco-2 cells using an anti-
dsDNA antibody (second antibody: Alexa Fluor 488–conjugated anti-mouse). Arrows indicate representative cytoplasmic dsDNA spots. Bars, 10 µm. (C) qPCR of 
Ifit1 and Ifit3 in intestinal organoids (Atg16l1fl/fl, Atg16l1ΔIEC, Stinggt, Mda5−/−) treated with or without rmIL-22 (1, 10, or 100 ng/ml) for 24 h (n = 3 each). (D) qPCR 
of Ifit1 in intestinal organoids (C57BL/6, Cgas−/−, Irf3−/−, Il28r−/−) treated with rmIL-22 (100 ng/ml) or PBS for 24 h (n = 3 each). (E) qPCR of Sting in intestinal 
organoids (Atg16l11fl/fl, Atg16l1ΔIEC) treated with rmIL-22 (1, 10, or 100 ng/ml; n = 3 each). (F) Protein lysates from intestinal organoids (Atg16l1fl/fl, Atg16l1ΔIEC) 
treated with either rmIL-22 (100 ng/ml) or hydroxyurea (HU; 2 µM) for 24 h were subjected to immunoblot analysis against STI NG. (G) Western blot analyses 
from intestinal organoids (Atg16l11fl/fl, Atg16l1ΔIEC) treated with rmIL-22 (100 ng/ml) for 24 h. Lysates were probed against pTBK1, TBK1, ATG16L1, and GAP DH. 
(H) Protein lysates from Caco-2 cells (ATG16L1+/+ vs. ATG16L1−/−), treated with IL-22 (100 ng/ml) for indicated time points were subjected to immunoblot analysis 
against indicated proteins. LE: longer exposure. (I) qPCR of Ifit1 and Ifit3 in intestinal organoids (C57BL/6J) treated with rmIL-22 (100 ng/ml) and BafA (5 nM) 
for 24 h (n = 3 each). Results (A–I) represent at least two independent experiments. Significance determined using two-tailed Student’s t test and expressed 
as the mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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To mechanistically prove that TNF is a downstream mediator 
of IL-22–induced cell death, we stimulated Atg16l1ΔIEC intesti-
nal organoids with IL-22 in the presence or absence of murine 
anti-TNF neutralizing antibody. We observed a dose-dependent 
protective effect of anti-TNF treatment, indicating that TNF acts 
as a downstream factor of IL-22–induced cell death (Fig. 6 I).
We next elucidated whether STI NG signaling is involved in 
IL-22–induced cell death in the context of impaired autophagy. 
We thus stimulated WT or Stinggt intestinal organoids with IL-22 
and BafA and assessed cell death in intestinal organoids by flow 
cytometry. Stinggt organoids were significantly protected from 
IL-22+BafA–induced cell death compared with WT organoids 
(Fig. 7, A–C). Since IFN-I induces MLKL expression (Günther et al., 
2016), a central regulator of necroptosis, we investigated whether 
IL-22/STI NG–induced cell death depends on MLKL. IL-22+ 
BafA–induced cell death was significantly lower in Mlkl−/− com-
pared with WT intestinal organoids (Fig.  7, D–F). Thus, con-
sistent with a recent report (Legarda et al., 2016) we conclude 
that IL-22/STI NG–dependent cell death involves MLKL-depen-
dent necroptosis.
Figure 4. IL-22 induces ileal inflammation in Atg16l1ΔIEC mice. (A) Stimulation scheme of Atg16l1fl/fl and Atg16l1ΔIEC mice (n = 5/5/5/5). Mice were treated 
with 2 µg/20 mg bodyweight of rmIL-22 i.p. every day over the course of 6 d. (B) Weight loss curve. (C) Statistical evaluation of the histological inflammation 
score in colon sections. (D–K) Histological evaluation of small intestinal sections with representative pictures and absolute quantification for H&E (D and E), 
TUN EL (F and G), and γH2AX (H and I; n = 5 each). Representative IF staining and statistical evaluation of small intestinal sections stained against pTBK1 (sec-
ond antibody: Alexa Fluor 546–conjugated anti-rabbit; red) and counterstained with DAPI and anti-E-cadherin (second antibody: Alexa Fluor 488–conjugated 
anti-mouse; green; J and K; n = 5 each). For quantification, a minimum of 100 crypts/intestine were assessed in each treatment group by two independent 
observers. Bars, 100 µm. (L) Gene expression of Tnf, Ifit1, Ifit3, and Cxcl10 from small intestinal crypts (n = 4 each). Results represent one experiment. Signif-
icance determined using two-tailed Student’s t test and expressed as the mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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IFN-I synergistically contributes to the IL-22–induced ileitis of 
Atg16l1ΔIEC mice
We next assessed the contribution of IFN-I signals to the IL-22–
driven ileitis in Atg16l1ΔIEC mice. In this experiment, mice re-
ceived a slightly harsher DSS regimen of 2% DSS for a total of 5 d 
to also induce robust colonic inflammation. In addition, Atg16l1fl/fl 
and Atg16l1ΔIEC mice received rmIL-22 i.p. every other day for 10 
d. To block the IFN-I pathway, one group of mice additionally re-
ceived a blocking antibody against the common IFN α/β recep-
tor (IFN AR; anti-IFN AR) at days 0, 2, 4, and 6 (Yang et al., 2015; 
Figure 5. IL-22 aggravates epithelial cell death–mediated inflammation in Atg16l1ΔIEC/Xbp1ΔIEC mice. (A) Treatment scheme of Atg16l1fl/fl/Xbp1fl/fl and 
Atg161ΔIEC/Xbp1ΔIEC mice (n = 7/7/7/6). (B–K) Histological evaluation of small intestinal sections with representative pictures and absolute quantification for 
H&E (B and C), TUN EL (D and E), and γH2AX (F and G; n = 5 each). Representative IF staining (including magnification inserts) and statistical evaluation of 
small intestinal sections stained against dsDNA (second antibody: Alexa Fluor 488–conjugated anti-mouse antibody; green; counterstained with DAPI; H and 
I) and pTBK1 (second antibody: Alexa Fluor 546–conjugated anti-rabbit; red), counterstained with DAPI and anti–E-cadherin (second antibody: Alexa Fluor 
488–conjugated anti-mouse; green; J and K; n = 5 each). For quantification a minimum of 100 crypts/intestine were assessed in each treatment group. Bars, 
100 µm. (L) qPCR of Ifnb and Tnf in ileal mucosa (n = 4 each). Results represent one experiment. Significance determined using two-tailed Student’s t test and 
expressed as the mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Aden et al. 
ATG16L1 licenses protective IL-22 signaling
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20171029
9
Fig. 8 A). With the harsher regimen of DSS treatment, Atg16l1ΔIEC 
mice displayed stronger histological signs of colonic inflamma-
tion compared with Atg16l1fl/fl animals. While IL-22 treatment 
did not significantly affect the severity of colonic inflammation 
(Fig. 8, B and C), it significantly exacerbated the severity of ileal 
inflammation in Atg16l1ΔIEC mice. Cotreatment of IL-22–stimu-
lated Atg16l1ΔIEC mice with anti-IFN AR antibody reduced the se-
verity of small intestinal inflammation (Fig. 8, D and E), which 
was again associated with decreased cell death in the crypt region 
(Fig. 8, F and G). This indicates that IFN-I synergizes with IL-22 
induced epithelial cell death and ileal inflammation in Atg16l1ΔIEC 
mice. To further assess to which extent IFN-I, independently of 
IL-22, influences epithelial cell death in Atg16l1ΔIEC in vitro, we 
stimulated Atg16l1ΔIEC and Atg16l1fl/fl intestinal organoids with 
IFN-β (1,000 U/ml) and assessed cell viability. IFN-β induced or-
ganoid cell death, which was significantly amplified in Atg16l1ΔIEC 
organoids (Fig. S5, A and B). To confirm the hypothesis that IFN-I 
contributes to ileal inflammation in Atg16l1ΔIEC mice independent 
of an exogenous IL-22 stimulus, we performed a 2% DSS colitis 
with either anti-IFN AR or with corresponding IgG control at days 
Figure 6. STI NG and IFN-I signals synergize in TNF induction and necroptosis in intestinal epithelial organoids. (A) Immunoblot analyses from protein 
lysates derived from Atg16l1fl/fl/Xbp1fl/fl and Atg16l1ΔIEC/Xbp1ΔIEC organoids stimulated with rmIL-22 (100 ng/ml) for 24 h and probed against pTBK1, TBK1, 
ATG16L1, and GAP DH. (B) Transcript levels of Tnf and Mlkl in small intestinal organoids (Atg16l1fl/fl/Xbp1fl/fl and Atg16l1ΔIEC/Xbp1ΔIEC) treated with rmIL-22 (100 
ng/ml) for 24 h as assessed by qPCR (n = 4 each). (C) Transcript levels of Cxcl1, Tnf in small intestinal organoids (C57BL/6, Stinggt) treated with rmIL-22 (100 ng/
ml) for 24 h as assessed by qPCR (n = 4 each). (D) Concentration of CXCL10 and TNF in the supernatant of intestinal organoids (C57BL/6, Stinggt) treated with 
rmIL-22 (100 ng/ml), bafilomycin A (BafA; 5 nM) or both for 24 h, as detected via ELI SA (n = 3 each). (E) qPCR of Cxcl1, Tnf in small intestinal organoids (Stinggt) 
treated with rmIL-22 (100 ng/ml) or IFN-β (1,000 IU/ml) or both for 24 h (n = 3 each). (F) qPCR of Cxcl10, Tnf in small intestinal organoids from C57BL/6 or 
Il28r−/− mice treated with rmIL-22 (100 ng/ml) for 24 h (n = 3 each). (G) qPCR of Mlkl and Tnf in small intestinal organoids (C57BL/6) treated with rmIL-22 (100 
ng/ml) or IFN-β (1,000 IU/ml) or both for 24 h (n = 3 each). (H) Concentration of TNF in the supernatant of intestinal organoids (C57BL/6) treated with rmIL-22 
(100 ng/ml) or IFN-β (1,000 IU/ml) or both for 24 h, as detected via ELI SA. (I) Assessment of dead cells from intestinal organoids (Atg16l1ΔIEC) stimulated with 
rmIL-22 (100 ng/ml) for 24 h in the absence or presence of anti-TNF antibody (10 and 100 ng/ml; n = 3 each). Results represent two independent experiments. 
Significance determined using two-tailed Student’s t test and expressed as the mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 7. IL-22–induced epithelial cell death depends on STI NG and MLKL. (A and B) Representative FACS plots (A) and flow cytometry analysis (B) of 
cell death of intestinal organoids (WT, Stinggt), treated with rmIL-22 (100 ng/ml) and BafA (5 nM) for 24 h and staind with PI (n = 3 each). (C) Representative 
pictures of intestinal organoids (WT, Stinggt), treated with rmIL-22 (100 ng/ml) and BafA (5 nM) for 24 h. Bars, 200 µm. (D and E) Representative FACS plots 
(D) and flow cytometry analysis (E) of cell death of intestinal organoids (WT, Mlkl−/−), treated with rmIL-22 (100 ng/ml) and BafA (5 nM) for 24 h and stained 
with PI (n = 3 each). (F) Representative pictures of intestinal organoids (WT, Mlkl−/−), treated with rmIL-22 (100 ng/ml) and BafA (5 nM) for 24 h. Bars, 200 µm. 
Results represent two independent experiments. Significance determined using two-tailed Student’s t test and expressed as the mean ± SEM. *, P < 0.05; **, 
P < 0.01; ***, P < 0.001.
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0, 2, 4, and 6 (Fig. S5 C) in the without IL-22 injection. Atg16l1ΔIEC 
mice displayed increased colonic inflammation, which was not 
significantly ameliorated by anti-IFN AR treatment (Fig. S5, D 
and E). However, and in line with our in vitro findings, treatment 
with anti-IFN AR antibody alone reduced small intestinal inflam-
mation and epithelial cell death in Atg16l1ΔIEC mice (Fig. S5, F–H).
The IL-22–IFN-I axis is associated with clinical outcome upon 
anti-TNF therapy in IBD patients
Prompted by our murine in vitro and in vivo findings we elu-
cidated whether the IL-22–ISG axis associates with disease se-
verity in IBD. We collected sigmoid biopsies before (week 0) or 
after (week 14) anti-TNF antibody treatment induction from 21 
IBD patients (n = 21; UC = 13 and CD = 8) and assessed muco-
sal mRNA expression by qPCR of IL22, TNF, and MLKL and a 
composite score of six IFN-I–inducible genes (IFI TM1, MXA, 
OAS3, IFIT1, IFI44L, and IFI16), termed “ISG score” hereafter, 
previously shown to robustly correlate with IFN-I signaling 
(Lübbers et al., 2013). Overall, IL22 mRNA levels were pos-
itively correlated with TNF and MLKL expression, as well as 
the ISG score (Fig. 9 A). In contrast to baseline expression, only 
IBD patients achieving clinical remission after anti-TNF treat-
ment (n = 21; remission: UC = 7 and CD = 7; nonremission: CD 
= 1 and UC = 6) displayed a significant reduction of mucosal 
IL22, TNF, and MLKL mRNA expression, as well as the ISG score 
levels (Fig. 9 B). Thus, our data indicate that the IL-22–ISG axis 
Figure 8. IFN-I signals contribute to IL-22–induced ileitis in Atg16l1ΔIEC mice. (A) Stimulation scheme of Atg16l1fl/fl and Atg16l1ΔIEC mice treated with rmIL-22 
and anti-IFN AR. Mice were treated with either rmIL-22 i.p. (2 µg/20 mg bodyweight) or PBS on days 0, 2, 4, 6, and 8. A group of mice received anti-IFN AR i.p. 
(10 mg/kg bodyweight). All mice were terminated at day 10. (B and C) Histological evaluation of colonic section with representative pictures (B) and absolute 
quantification for H&E (C; n = 5/8/6/8/8). Bars, 500 µm (upper); 200 µm (lower). (D–G) Histological evaluation of small intestinal sections with representative 
pictures and absolute quantification for H&E (D and E) and TUN EL (F and G); n = 5/8/6/8/8). Bars, 100 µm. Results represent one experiment. Significance 
determined using two-tailed Student’s t test (C, E, and G) and expressed as the mean ± SEM. *, P < 0.05; ***, P < 0.001.
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might be involved in therapy response to anti-TNF treatment 
in IBD patients.
Discussion
The interplay of hypomorphic autophagy function and increased 
ER stress in intestinal epithelial cells is an important part of 
the etiology of human IBD. Our data now provide evidence for 
a surprising link of this interplay to intestinal epithelial IL-22 
signaling. IL-22 normally plays an essential role in intestinal ho-
meostasis (Sabat et al., 2014). However, under certain conditions, 
IL-22 signaling may evoke tissue damage (Wang et al., 2017), leads 
to halted epithelial expansion in vitro (Lindemans et al., 2015), 
and may instead aggravate inflammatory responses (Zheng et 
al., 2007). A molecular explanation of this dichotomous role has 
remained obscure. Our data indicate that unrestricted and exces-
sive IL-22 signaling may indeed perpetuate intestinal inflamma-
tion, rather than resolve it. In our experiments, IL-22 effects on 
intestinal wound healing even in the autophagy-proficient set-
ting are strongly context dependent. In epithelial scratch assays, 
we show that immediate IL-22 stimulation after scratching leads 
to significantly improved wound healing (cell migration and pro-
liferation), whereas continuous IL-22 stimulation already before 
induction (pretreatment) impeded scratch closure. This is in line 
with reports showing time-restricted pulsatile IL-22 expression 
during intestinal wound healing (Huber et al., 2012). In active 
IBD, high numbers of IL-22 producing cells (Geremia et al., 2011) 
and elevated levels of IL22 mRNA and IL-22 protein have been 
documented in several independent studies (Brand et al., 2006; 
Pelczar et al., 2016; Feagan et al., 2017; Nikolaus et al., 2017). It 
is difficult to infer exact mucosal concentrations due to the spa-
tially restricted expression of IL-22; however, it seems likely that 
measurable elevation of serum concentrations in active IBD (in 
the range of up to 0.5 ng/ml; Nikolaus et al., 2017), as well as in 
vitro secretion capacity from biopsies from experimental mod-
els of intestinal inflammation (Bachmann et al., 2010), reflect 
local IL-22 levels, which may well reach the range of the con-
centrations (1–100 ng/ml) used in the present study. This is in 
Figure 9. The IL-22–IFN-I axis affects clinical out-
come upon anti-TNF therapy in IBD patients. (A) Lin-
ear regression of correlation of IL22, TNF, and MLKL or a 
composite score (Lübbers et al., 2013) of six IFN stimula-
tory genes (ISG) in sigmoid biopsies from IBD patients (n 
= 21). (B) Relative mRNA expression of IL22, TNF, MLKL, 
or a composite score of six ISG in sigmoid biopsies from 
human IBD patients before (week 0) or after anti-TNF 
therapy (week 14) clustered according to clinical remis-
sion status (remission: UC = 7, CD = 7; nonremission: CD 
= 1, UC = 6). Significance determined using Spearman 
test for correlation (A) or Mann-Whitney test (B) and 
expressed as the mean ± SEM.
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line with another study (Lindemans et al., 2015) indicating that 
deleterious IL-22 effects may correlate with higher concentra-
tions. Moreover, recombinant IL-22Fc has been used in concen-
trations of 120 µg/kg bodyweight in humans (Lekkerkerker et 
al., 2017), indicating that the in vivo concentrations used in our 
mouse studies are highly relevant if also therapeutic application 
of IL-22 is considered.
Deficiency of Atg16l1 aggravates the detrimental effects of 
IL-22 signaling, characterized by excessive epithelial cell death 
in vitro and in vivo. We show that the concomitant induction 
of ISG and TNF is dependent on IL-22–induced activation of 
cGAS–STI NG signaling. While physiologically detectable after 
IL-22 stimulation of WT primary intestinal epithelial cells, the 
cGAS–STI NG response is strongly increased in the absence of 
functional Atg16l1. This indicates that Atg16l1 may be either im-
portant for removal of active STI NG signaling complexes (Saitoh 
et al., 2009; Bartsch et al., 2017; Prabakaran et al., 2018) or may 
be involved in the generation of the endogenous activation prin-
ciple, e.g., by aggravating the ER stress-mitochondria axis or im-
pairing maintenance of DNA integrity, which may lead to the 
induction of nuclear DNA damage and dsDNA release (Liu et al., 
2015; Qiang et al., 2016; Wang et al., 2017).
Atg16l1ΔIEC mice exposed to the DSS even at low doses de-
velop significant inflammation and epithelial cell death in the 
terminal ileum, although the irritant usually only elicits colonic 
inflammation. Of note, Atg16l1ΔIEC mice display a significant 
degree of enhanced epithelial cell death in the small intestine 
even under baseline condition. Both phenotypes are aggravated 
upon cotreatment with IL-22. In our hands, the effect seemed to 
be restricted to the small intestine, as exogenous IL-22 was not 
able to potentiate DSS-induced inflammation in the colon. Cor-
roborating the specific effect on small intestinal inflammation, 
IL-22 treatment also worsened spontaneous CD-like ileitis and 
epithelial cell death in Atg16l1ΔIEC/Xbp1ΔIEC mice, which coincided 
with increased mRNA levels of Tnf and Ifnb. Our observations 
thus indicate a tissue specific interplay of ATG16L1-dependent 
autophagy, necroptosis, and IL-22 signaling in the small intesti-
nal mucosa, which is in agreement of Atg16l1’s role as a CD risk 
gene with a predominant ileal phenotype (Durães et al., 2013). It 
must be noted that our study setup solely focuses on the interac-
tion of IL-22 signaling with impaired autophagy and ER stress in 
the intestinal epithelial layer. It will be interesting to elucidate 
the interplay of ATG16L1 and IL-22 with other cell types, e.g., im-
mune cells, that might critically modulate epithelial remodeling 
(Zheng et al., 2007; Aden et al., 2016).
Dysregulated necroptosis is an important driver of epithelial 
cell death in the gut and is an active principle in chronic inflam-
matory states including human IBD (Duprez et al., 2011; Günther 
et al., 2011; Welz et al., 2011). It has been recently reported that 
Atg16l1ΔIEC intestinal organoids are more susceptible to TNF-in-
duced necroptosis, which underscores the importance of a suffi-
cient autophagy machinery for fine tuning of cell death pathways 
(Matsuzawa-Ishimoto et al., 2017). We here provide evidence that 
dysfunctional autophagy (specifically, genetic defects in Atg16l1) 
may transform regenerative IL-22 signaling into a stimulus for 
MLKL-dependent epithelial necroptosis. Our data indicate that 
IL-22–dependent necroptosis requires enhanced STI NG signal-
ing as (1) IL-22–induced TNF and ISG induction is inhibited in 
Stinggt intestinal organoids, and (2) IL-22–induced cell death in 
autophagy-deficient cells is rescued in Stinggt and in Mlkl−/− in-
testinal organoids.
STI NG activation in this scenario leads to a strong epithelial 
ISG response. Although it has been reported that specific IFN-I 
target genes can be directly activated without prior IFN-I secre-
tion, canonical ISG induction is thought to require IFN-I signal-
ing (Schneider et al., 2014). We provide evidence that such IFN-I 
signals might, either directly or indirectly, be involved in the ob-
served cell death phenotype. (1) IFN-β leads to the induction of 
MLKL and TNF and cell death in epithelial organoids, which is 
aggravated in Atg16l1-deficient conditions. (2) Blocking the IFN-I 
receptor with a blocking anti-IFN AR antibody leads to ameliora-
tion of disease severity. However, it must be noted that epithelial 
cell death and ileal inflammation in Atg16l1ΔIEC mice were also 
ameliorated in the DSS model without additional IL-22. This in-
dicates that the pathological consequence of exacerbated IFN-I 
signaling in the autophagy-deficient situation is not strictly 
dependent on IL-22, although we cannot rule out endogenous 
IL-22 signaling in the DSS model. It must also be pointed out that 
most of the observations in the organoid experiments are based 
on mRNA levels, which in our hands are more reliable than as-
saying secreted protein levels in the supernatant, potentially due 
to Matrigel embedding and low cell density. Although we have 
clearly detected elevated IFN-β upon IL-22 stimulation in vivo in 
the spontaneous ileitis in Atg16l1ΔIEC/Xbp1ΔIEC mice, the exact role 
of autocrine IFN-I hence remains to be elucidated. STI NG-depen-
dent necroptosis might be potentiated through IFN-I from other 
cellular sources, but might also be influenced by an impact of 
ATG16L1 on IFN-I independent mechanisms of STI NG-induced 
cell death (Sze et al., 2013; Cerboni et al., 2017; Gaidt et al., 2017; 
Larkin et al., 2017).
Collectively, our data point to a crucial role of autophagy and ER 
stress in controlling IL-22 signaling at the ileal mucosal barrier. It 
is conceivable that a switch to excessive IFN-I and TNF induction 
and subsequent programmed cell death may indeed be protec-
tive in virus infections, where often autophagy and resolution of 
ER stress are impaired (Hernández et al., 2015; Kuriakose et al., 
2016; Mouna et al., 2016). Under conditions of chronic intestinal 
inflammation and with clear genetic “hits” to the autophagic and 
ER stress machinery like in human IBD, such a fate of IL-22 signals 
may crucially contribute to a vicious circle of tissue damage and 
inflammation. With recombinant IL-22 fusion proteins currently 
being developed as potential therapy in human intestinal inflam-
mation as GvHD (clinicaltrials.gov identifier: NCT02406651) and 
IBD (clinicaltrials.gov identifier: NCT02749630; Stefanich et al., 
2018), this dichotomy may have important clinical implications.
Materials and methods
Antibodies and reagents
Recombinant murine and human IL-22, epidermal growth factor, 
and IL-10 were purchased from Peprotech; TM was purchased 
from Calbiochem; bafilomycin A1 was purchased from Enzo; 
rapamycin was purchased from Sigma Aldrich; and iSTAT3 
inhibitor was purchased from EMD Millipore. Recombinant 
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murine IFN-β was purchased from R&D. Antibodies targeting 
ATG16L1 (D6D5), γH2AX (Ser139; D17A3), STI NG (D2P2F), pTBK1 
(Ser172; D52C2), TBK1 (D1B4), MLKL (D6W1K), pIRF-3 (Ser396; 
4D4G), IRF-3 (D83B9; all from Cell Signaling Technology), 
pMLKL (Ser345; EPR9515(2); Abcam), β-ACT IN (Sigma Aldrich), 
and GAP DH (Santa Cruz) were used for immunoblot analysis. 
Neutralizing anti-TNF (MP6-XT22) antibody was purchased 
from Biolegend. For immunohistochemistry (IHC), antibodies 
against γH2AX (Ser139; Cell Signaling Technology) were applied. 
Anti-dsDNA (HYB331-01) antibody for immunofluorescence (IF) 
staining was purchased from Santa Cruz. Propidium iodide (PI) 
was purchased from BD Biosciences. In vivo IFN-I blockade was 
established using anti-IFN AR antibody (clone: MAR1-5A3; Biocx-
ell), which was used as described before (Yang et al., 2015). Mu-
rine anti-TNF antibody was purchased from Biolegend.
Cell culture
HT-29 and Caco-2 human colorectal adenocarcinoma cells were 
derived and authenticated from the Deutsche Sammlung von 
Mikroorganismen und Zellkulturen. Cell lines were seeded in 
6-, 12-, or 24-well plates, respectively. Using the CRI SPR/Cas9 
technology, three independent ATG16L1-deficient Caco-2 cell 
clones were established. Cells were cultured in DMEM + 10% FCS 
or MEM + 20% FCS, until confluency. Before stimulation, cells 
were serum-starved by incubating DMEM + 1% FCS medium or 
MEM + 1% FCS for 24 h. Mycoplasma infection of cell lines were 
excluded by applying biweekly mycoplasma testing using My-
coalert (Lonza).
Epithelial scratch assay
Scratch assays were performed as described before (Liang et 
al., 2007). In brief, using a P100 pipette tip, an epithelial wound 
was created by rapidly scratching a fully confluent cellular 
monolayer. A line was drawn on the bottom of each well using a 
scalpel to identify same wound areas directly after creating the 
wound and after 24 h of incubation. Epithelial wound closure 
was assessed by imaging using Zeiss Axio Vert.A1 and digital 
measurement of the cell free area using AxioVision LE (Zeiss) 
software. The relative wound closure is calculated as follows: 
Relative wound closure = 1 – (wound area after 24 h / starting 
wound area).
Mice
Villin(V)-cre+; Xbp1fl/fl (Xbp1ΔIEC) (Niederreiter et al., 2013), 
Villin(V)-cre+; Atg16l1fl/fl (Atg161ΔIEC) (Adolph et al., 2013), Vil-
lin(V)-cre+; Atg16l1fl/fl/Xbp1fl/fl (Atg16l1ΔIEC/Xbp1ΔIEC) (Adolph 
et al., 2013), Villin(V)-cre+; Stinggt, Mda5−/−, and Mlkl−/−, back-
crossed for at least six generations on a C57BL/6 background, 
were used at an age of 8–12 wk for all experiments with appro-
priate genotype littermate controls. Cgas−/− were provided by 
A. Roers (Technical University Dresden, Dresden, Germany), 
Il28r−/− were provided by P. Staeheli (University Hospital 
Freiburg, Freiburg, Germany), and Irf3−/− were provided by M. 
Brinkmann (Helmholtz Centre for Infection Research, Braun-
schweig, Germany). For Il28r−/− and Irf3−/−, Stinggt, Mda5−/−, and 
Mlkl−/−, nonlittermate C57BL/6 animals at an age of 8–12 wk were 
used as controls animals and were declared as WT.
Ormdl3fl/fl mice were generated in cooperation with Taconic. 
In brief, proximal loxP sites were inserted into Ormdl3 gene on 
exon 2. A distal loxP site was introduced with an FRT flanked 
neomycin selection cassette within exon 4. The resultant mouse 
line was bred with deleter-mice constitutively expressing Flp re-
combinase to remove the neomycin selection cassette, creating 
an Ormdl3f/+l mouse in which Ormdl3 exons 2–4 were flanked 
by two loxP sites. After backcrossing onto C57BL/6, these mice 
were crossed with V-cre+ mice resulting in V-cre; Ormdl3fl/fl 
mice with intestinal-epithelial-cell-specific Ormdl3 deletion 
(Ormdl3ΔIEC). Ormdl3fl/fl mice were crossed with Atg16l1ΔIEC 
mice to develop V-cre+;Atg16l1fl/fl;Ormdl3fl/fl (Atg16l1ΔIEC/ 
Ormdl3ΔIEC) mice.
All mice were maintained in a specific pathogen–free fa-
cility, and quarterly health report did not indicate presence of 
pathogenic bacteria, viruses, or protozoa. All Atg16l1fl/fl colonies 
were norovirus free. Littermates were cohoused throughout the 
entire length of the experiments in a maximum genotype ratio 
of 1:2 (i.e., two fl/fl animals cohoused with a single ΔIEC). Mice 
were provided with food and water ad libitum and maintained 
in a 12-h light–dark cycle under standard conditions at Kiel Uni-
versity (Atg161ΔIEC, Xbp1ΔIEC, Atg161ΔIEC/Ormdl3ΔIEC, Mlkl−/−), the 
University of Cambridge (Atg161ΔIEC/Xbp1ΔIEC), University Hos-
pital Bonn (Stinggt and Mda5−/−), Technical University Dresden 
(Cgas−/−), University Hospital Freiburg (Il28r−/−), and Helmholtz 
Centre for Infection Research (Irf3−/−).
Tail or ear biopsy genomic DNA was used for genotyping of 
respective mouse strains. For experiments including application 
of recombinant murine IL-22 or DSS experiments equal numbers 
(minimum n = 5 per genotype; see figure legends for details) of 
male and female animals were used. Procedures involving animal 
care were conducted in conform to national and international 
laws and policies and appropriate permission. All experiments 
were performed in accordance with the guidelines for Animal 
Care of Kiel University and University of Cambridge (for exper-
iments involving Atg161ΔIEC/Xbp1ΔIEC mice).
In vivo treatment of mice
Atg16l1ΔIEC or Atg16l1fl/fl mice were treated with either 2 µg/20 mg 
bodyweight recombinant murine IL-22 (Peprotech) or PBS i.p. 
for indicated time before being sacrificed for intestinal epithelial 
cell isolation as described elsewhere (Pickert et al., 2009). In ad-
dition, Atg16l1ΔIEC or Atg16l1fl/fl mice were supplied with 2% DSS 
(MP Biomedical) dissolved in autoclaved drinking water on day 
1 for three consecutive days followed by 2 d of regular drinking 
water. Disease Activity Index was assessed as described previ-
ously (Siegmund et al., 2001). Atg16l1ΔIEC/Xbp1ΔIEC or Atg16l1fl/fl/
Xbp1fl/fl mice were treated with either 2 µg/20 mg bodyweight 
recombinant murine IL-22 (Peprotech) or PBS i.p. every other 
day for 13 d (seven injections in total) before being sacrificed for 
intestinal epithelial cell isolation as described elsewhere (Pickert 
et al., 2009). For the anti-IFN AR antibody rescue experiment, 
Atg16l1ΔIEC or Atg16l1fl/fl mice were treated with anti-IFN AR anti-
body f (10 mg/kg bodyweight; clone: MAR1-5A3) at days 0, 2, 4, 
and 6 of DSS colitis. Mice were additionally supplied with 2% DSS 
dissolved in autoclaved drinking water from day 0–5 followed by 
5 d of regular drinking water.
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Histopathological analyses of murine small intestinal tissue
Post mortem, the entire small intestine was excised and separated 
longitudinally into two equal parts. The longitudinal section was 
rolled up, starting with the distal part thereby having the distal 
ileum at the very inner layer and the proximal intestine at the 
very outer layer. The entire specimen was fixed in 10% formalin. 
Paraffin sections were cut and stained with H&E. Histological 
scoring was performed in a blinded fashion by two independent 
observers. The histological score displays the combined score of 
inflammatory cell infiltration and tissue damage as described 
elsewhere (Adolph et al., 2013).
IHC and IF
For IHC and IF staining, 5-µm sections of paraffin-embed-
ded colon/ileum Swiss rolls were deparaffinized with Tyrol 
substitute (Roth).
For IHC, slides were incubated in citrate buffer for 3 min and 
subsequently blocked with blocking serum (Vectastain) for 20 
min. Primary antibodies were incubated overnight. Sections 
were washed, incubated with secondary antibodies and DAB 
substrate (Vectastain ABC kit). For TUN EL assay, slides were sub-
jected to Apop Tag Plus Peroxidase In situ Apoptosis Detection kit 
(Merck Millipore) according to manufacturer’s protocol.
For IF staining of tissue, paraffin-embedded sections were 
blocked in PBS containing 5% BSA and 0.2% Triton X-100 for 30 
min after removal of citric buffer and before incubation of a pri-
mary antibody overnight at 4°C. Secondary antibodies conjugated 
with fluorophores were added after washing steps with PBS for 
45 min. Then, tissue was counterstained with DAPI and DRAQ5 
and then mounted with fluorescence mounting medium (DAKO).
For IF staining of Caco-2 cells, cells were fixed on cover slides 
using 4% paraformaldehyde for 30 min at room temperature. 
After washing steps, cells were permeabilized for 3 min at room 
temperature using PBS containing 1% Triton X-100 and 5% BSA. 
Cells were blocked using 5% goat serum for at least 60 min at 
room temperature. The further staining procedure was identical 
to the IF protocol for tissues.
For quantification of dsDNA or pTBK-1 a minimum of 100 
crypts/intestine were assessed in each treatment group and sta-
tistical evaluation showing the mean number of dsDNA+ or pTBK+ 
cells per treatment group. Slides were visualized by an AxioIm-
ager Z1 microscope (Zeiss; Germany). Pictures were captured by 
a digital camera system (AxioCam HrC/HrM, Zeiss). Measure-
ments were made using a semi-automated image analysis soft-
ware (AxioVision version 08/2013).
Cultivation of murine intestinal organoids
Mouse intestinal organoids were cultivated as described before 
(Sato et al., 2009). In brief, small intestine was removed and 
cleared of intestinal content by flushing the intestine with HBSS. 
After removal of residual fat and Peyer’s patches, the intestine 
was cut longitudinally and then laterally in pieces of 0.5 cm. 
Intestinal pieces were incubated in ice-cold PBS + 10 nM EDTA 
for 10 min for four times, intermitted by vigorous shaking and 
replacement with fresh PBS + 10 nM EDTA after every shaking 
process. The crypt suspension was then strained through a 100-
µm strainer, followed by a spin with 1,200 rpm at 4°C. Pure ep-
ithelial crypts were suspended in Matrigel (BD Bioscience) to a 
concentration of 5–10 crypts/1 µl Matrigel, embedded in 24-well 
plates and cultivated in intestinal stem cell medium (IntestiCult 
Organoid Growth Medium [Mouse], StemCell Technologies, Inc.) 
based on previously described organoid medium containing mu-
rine EGF, murine Noggin, and human R-Spondin 1 (Sato et al., 
2009). Medium was changed every other day, and organoids 
were stimulated after 3–6 d of cultivation after passage.
Epithelial cell death assay
Organoids derived from Atg16l1ΔIEC or Atg16l1fl/fl mice were 
seeded into 96-well plates. For FACS-based cell death assay using 
PI, organoids were dissociated into single cells using TrypLE Ex-
press (Thermo Fisher Scientific). Cells were then incubated in PI 
for 10 min before FACS assay using FACScalibur (BD Bioscience). 
10,000 cells were gated excluding doublets or nondissociated cell 
groups. The fraction of cells positive for PI staining was consid-
ered as dead cells (Dannappel et al., 2014). For microscopic as-
sessment, 1 µl PI was added to 500 µl medium overnight. Medium 
was removed and matrigel droplets containing the organoids 
were washed with PBS. Merged images were then captured using 
multidimensional imaging with brightfield and RFP fluorescence 
filter using Zeiss Axio Vert.A1.
Immunoblot analysis
Cells were lysed using SDS-based DLB buffer + 1% Halt Protease 
inhibitor cocktail (Thermo Fisher Scientific) before heating on 
95°C for 5 min and followed by sonification for 5 s twice. To re-
move cell remnants, lysates were centrifuged at 16,000 g for 15 
min at 4°C. For protein extraction of organoids, Matrigel was re-
moved by several centrifugation steps at 4°C followed by lysis as 
described above. Afterward, equal amounts of lysates containing 
Laemmli buffer were heated at 95°C and electrophoresed on 12% 
polyacrylamide gels under standard SDS-PAGE conditions before 
being transferred onto a polyvinylidene fluoride membranes (GE 
Healthcare). Protein loaded membranes were blocked with 5% 
milk in TBS-T, incubated with primary antibody overnight and 
with HRP-conjugated secondary antibody for 1  h at indicated 
concentrations. Proteins were detected using Amersham ECL 
Prime Western Blot Detection Reagent (GE Healthcare).
ELI SA
Supernatants from stimulated cell cultures were analyzed for 
indicated protein concentration using ELI SA kit according to 
manufacturer’s protocol for IL-8 (Thermo Fisher Scientific) and 
murine TNF and murine Cxcl10 (Peprotech).
cDNA synthesis and gene expression analysis
mRNA isolation of PBS washed cells, snap -frozen tissue, and 
PBS -washed Matrigel containing organoids was performed using 
RNEasy kit (Qiagen). cDNA synthesis was performed using Re-
vertAid Premium cDNA Synthesis kit (Fermentas) according to 
manufacturer’s protocol. Gene expression was subjected to the 
cDNA samples using SYBR Green qPCR or TaqMan assays, which 
were purchased from Applied Biosystems. Reactions were per-
formed on the Applied Biosystems 7900HT Fast Real-Time PCR 
System (Applied Biosystems), and relative transcript levels were 
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determined using Actb (TaqMan and SYBR Green) and Gapdh 
(SYBR Green) as a housekeeper. Primer sequences were retrieved 
designed using Primer3 software version 0.4.0 (Untergasser et 
al., 2012), except for those individually referenced (for sequences 
see Table S7). TaqMan Probes were derived from Applied Biosys-
tems (for TaqMan probe IDs see Table S8).
Transcriptomics analysis
RNaseq was conducted on small intestinal organoids derived 
from Atg16l1ΔIEC and Atg16l1fl/fl mice (n = 4) that were treated 
with recombinant murine IL-22 (10 ng/ml) or controls. Samples 
were sequences on Illumina HiSeq3000 using Illumina total 
RNA stranded TruSeq protocol. An average of ∼28 million 150-
nt paired-end reads was sequenced for each sample. Raw reads 
were preprocessed using cutadapt (Martin, 2011) to remove 
adapter and low quality sequences. RNaseq reads were aligned 
to the mm10/Ensemble (GrCm38) reference genome with Top-
Hat2 (Trapnell et al., 2012). Data were deposited in the NCBI 
Gene Expression Omnibus under GSE119354. Gene expression 
values of the transcripts were computed by HTSeq (Anders et 
al., 2015). Differential gene expression levels were analyzed 
and visualized by the Bioconductor package DESeq2 (Love et al., 
2014). The overall effect of IL-22 treatment of organoid cells on 
WT and Atg16l1ΔIEC mice was obtained by multifactorial experi-
mental design of DESeq2. Likelihood ratio test was used to assess 
the significant differentially expressed genes (DEG) of WT/KO-
IL-22 treatment interaction of Atg16l1ΔIEC mice (P value <0.01). 
Venn diagrams were drawn using VennDiagram package in R 
(Chen and Boutros, 2011). To gain insight into the nature of DEGs 
uniquely expressed in Atg16l1fl/fl and Atg16l1ΔIEC mice upon IL-22 
treatment (up- and down-regulated), GO terms obtained within 
the category of biological processes using the InnateDB database 
(Breuer et al., 2013).
Candidate validation in human IBD samples
For validation of ISG, IL22, TNF, and MLKL signatures under anti- 
TNF therapy we recruited a total of 22 IBD patients including 13 
patients with UC and 9 patients with CD. The study was approved 
by the ethics committee of Kiel University (A 124/14) and subjects 
provided written informed consent. We included patients with 
active colonic disease who received vedolizumab or infliximab 
for induction of remission in standard medical care. Indication 
and choice of treatment were not part of the study protocol. Pa-
tients were investigated 24 h before initiation of treatment and 
at weeks 2, 6, and 14 after initiation of treatment. At each time 
point, 60 ml of peripheral blood were obtained and a sigmoid-
oscopy was performed, in which up to eight biopsies were taken 
from the sigmoid colon. Peripheral blood and biopsies from the 
sigmoid colon of patients were obtained within 24 h before ini-
tiation of treatment and immediately before administration of 
infliximab at weeks 2, 6, and 14. CD patients with a Harvey-Brad-
shaw Index (HBI) of ≤4 were considered to be in remission, those 
with ≥5 to have active disease. Patients with UC and a total Mayo 
Score of ≤2 (bleeding 0 and endoscopy ≤1) were considered to be 
in remission, those with ≥3 to have active disease. To create an 
ISG score we assessed the expression of a total of six known ISG 
(IFI TM1, MX1, OAS3, IFIT1, IFI44l, and IFI16), which are shown 
to correlate strongest with type I IFN expression in human, as 
described previously (Lübbers et al., 2013). An ISG score was cal-
culated by averaging the relative expression of these genes.
Generation of CRI SPR guided deletion of 
ATG16L1−/− Caco-2 cells
A CRI SPR/Cas9 vector (Thermo Fisher Scientific) was created ac-
cording to the manufacturer’s instructions, using a dsDNA oligo 
targeting ATG16L1 (5′-GCA GCA AGT GAC ATG TCGT-3′). The vector 
was transfected with Lipofectamine 3000 into Caco-2 cells, and 
clonal cell lines were generated. Knockout clones were selected 
by verifying absence of ATG16L1 protein by Western blot analysis.
Statistical information
Statistical analysis was performed using GraphPad Prism (ver-
sion 4.0) for Windows software (GraphPad Software). No data 
are excluded for analyses. Statistical significance was evaluated 
by Mann–Whitney U-test for nonparametric data or the Student's 
t test for parametric data unless indicated otherwise. P values 
<0.05 were considered statistically significant.
Online supplemental material
Fig. S1 shows that IL-22 increased proinflammatory signals in 
the context of increased ER stress or impaired autophagy. Fig. 
S2 shows that IL-22–induced ER stress, controlled by STAT3 
and autophagy, impairs intestinal regeneration. Fig. S3 shows 
additional data on cell death assay and transcriptome analysis 
of IL-22–treated Atg16l1ΔIEC organoids. Fig. S4 shows that the in-
terplay of ER stress and autophagy is linked to increased IL-22–
induced STI NG/IFN-I activation. Fig. S5 shows that the impact 
of IFN-I signaling on ileitis in Atg16l1ΔIEC mice is independent of 
exogenous IL-22 administration. Table S1 shows up-regulated 
genes in untreated Atg16l1fl/fl intestinal organoids compared to 
Atg16l1ΔIEC. Table S2 shows down-regulated genes in untreated 
Atg16l1fl/fl intestinal organoids compared to Atg16l1ΔIEC. Table S3 
shows genes uniquely up-regulated in Atg16l1fl/fl + IL-22–treated 
intestinal organoids. Table S4 shows genes uniquely down-regu-
lated in Atg16l1fl/fl + IL-22–treated intestinal organoids. Table S5 
shows genes uniquely up-regulated in Atg16l1ΔIEC + IL-22–treated 
intestinal organoids. Table S6 shows genes uniquely down-regu-
lated in Atg16l1ΔIEC + IL-22–treated intestinal organoids. Table S7 
shows SYBR Green primers used for quantitative real-time PCR 
(qRT-PCR). Table S8 shows TaqMan probes used for quantita-
tive real-time PCR.
Acknowledgments
We gratefully appreciate the technical assistance of Maren 
Reffelmann, Dorina Ölsner, Tanja Klostermeier, Katharina 
Göbel, Karina Greve, Melanie Nebendahl, Sabine Kock, and 
Tatjana Schmidtke. 
This work was supported by Deutsche Forschungsgemein-
schaft DFG ExC306 Excellence Cluster Inflammation at Interfaces 
(to P. Rosenstiel), DFG ExC1023 Excellence Cluster ImmunoSen-
sation (to W. Barchet and G. Hartmann), the DFG RTG1743 Re-
search Training Group 1743 (to P. Rosenstiel), the DFG CRC877 
Collaborative Research Center B9 project (to P. Rosenstiel), the 
Aden et al. 
ATG16L1 licenses protective IL-22 signaling
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20171029
17
DFG CRC1182 C2 (to P. Rosenstiel), the EU H2020 Project SYS 
CID no. 733100 (to P. Rosenstiel), the Schleswig Holstein Ex-
cellence Chair program (to P. Rosenstiel), the Wellcome Trust 
Investigator award (grant no. 106260/Z/14/Z; to A. Kaser), Eu-
ropean Research Council under the European Community's Sev-
enth Framework Program (grant no. FP7/2007-2013)/ERC StG 
agreement no. 260961 (to A. Kaser), ERC AdG agreement 323040 
(to M. Pasparakis), and Horizon 2020 ERC CoG agreement no. 
648889 (to A. Kaser); Cambridge Biomedical Research Centre 
(to A. Kaser), and the National Institutes of Health (grant nos. 
DK044319, DK051362, DK053056, and DK088199 to R.S. Blum-
berg) and grant to the Harvard Digestive Diseases Center (grant 
no. DK034854 to R.S. Blumberg).
The authors declare no competing financial interests.
Author contributions: K. Aden, F. Tran, G. Ito, and P. Rosen-
stiel designed the study; K. Aden, F. Tran, G. Ito, J.W. Kuiper, M. 
Tschurtschenthaler, K. Bartsch, A. Luzius, M. Jentzsch, S. Lip-
inski, S.T. Stengel, J. Bhattacharyya, R. Häsler, M. Falk-Paulsen, 
L. Welz, R. Schwarzer, B. Rabe, R.S. Blumberg and R. Sheiba-
ni-Tezerji performed experiments and analyzed the data. W. 
Barchet, S. Krautwald, G. Hartmann, and M. Pasparakis provided 
transgenic mice and revised the paper for important intellectual 
content; K. Aden, F. Tran, R.S. Blumberg, S. Schreiber, A. Kaser, 
and P. Rosenstiel wrote the manuscript.
Submitted: 6 June 2017
Revised: 11 January 2018
Accepted: 20 August 2018
References
Aden, K., A. Rehman, M. Falk-Paulsen, T. Secher, J. Kuiper, F. Tran, S. Pfeuffer, 
R. Sheibani-Tezerji, A. Breuer, A. Luzius, et al. 2016. Epithelial IL-23R Sig-
naling Licenses Protective IL-22 Responses in Intestinal Inflammation. 
Cell Reports. 16:2208–2218. https:// doi .org/ 10 .1016/ j .celrep .2016 .07 .054
Adolph, T.E., M.F. Tomczak, L. Niederreiter, H.-J. Ko, J. Böck, E. Marti-
nez-Naves, J.N. Glickman, M. Tschurtschenthaler, J. Hartwig, S. Hosomi, 
et al. 2013. Paneth cells as a site of origin for intestinal inflammation. 
Nature. 503:272–276. https:// doi .org/ 10 .1038/ nature12599
Anders, S., P.T. Pyl, and W. Huber. 2015. HTSeq--a Python framework to work 
with high-throughput sequencing data. Bioinformatics. 31:166–169. 
https:// doi .org/ 10 .1093/ bioinformatics/ btu638
Bachmann, M., K. Horn, I. Rudloff, I. Goren, M. Holdener, U. Christen, N. Dar-
sow, K.-P. Hunfeld, U. Koehl, P. Kind, et al. 2010. Early production of 
IL-22 but not IL-17 by peripheral blood mononuclear cells exposed to 
live Borrelia burgdorferi: the role of monocytes and interleukin-1. PLoS 
Pathog. 6:e1001144. https:// doi .org/ 10 .1371/ journal .ppat .1001144
Barber, G.N. 2015. STI NG: infection, inflammation and cancer. Nat. Rev. Immu-
nol. 15:760–770. https:// doi .org/ 10 .1038/ nri3921
Bartsch, K., K. Knittler, C. Borowski, S. Rudnik, M. Damme, K. Aden, M.E. Spe-
hlmann, N. Frey, P. Saftig, A. Chalaris, and B. Rabe. 2017. Absence of RNase 
H2 triggers generation of immunogenic micronuclei removed by autoph-
agy. Hum. Mol. Genet. 26:3960–3972. https:// doi .org/ 10 .1093/ hmg/ ddx283
Brand, S., F. Beigel, T. Olszak, K. Zitzmann, S.T. Eichhorst, J.-M. Otte, H. 
Diepolder, A. Marquardt, W. Jagla, A. Popp, et al. 2006. IL-22 is increased 
in active Crohn’s disease and promotes proinflammatory gene expres-
sion and intestinal epithelial cell migration. Am. J. Physiol. Gastrointest. 
Liver Physiol. 290:G827–G838. https:// doi .org/ 10 .1152/ ajpgi .00513 .2005
Breuer, K., A.K. Foroushani, M.R. Laird, C. Chen, A. Sribnaia, R. Lo, G.L. Win-
sor, R.E.W. Hancock, F.S.L. Brinkman, and D.J. Lynn. 2013. InnateDB: 
systems biology of innate immunity and beyond--recent updates and 
continuing curation. Nucleic Acids Res. 41(Database issue, D1):D1228–
D1233. https:// doi .org/ 10 .1093/ nar/ gks1147
Cadwell, K., J.Y. Liu, S.L. Brown, H. Miyoshi, J. Loh, J.K. Lennerz, C. Kishi, W. 
Kc, J.A. Carrero, S. Hunt, et al. 2008. A key role for autophagy and the 
autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Na-
ture. 456:259–263. https:// doi .org/ 10 .1038/ nature07416
Cadwell, K., K.K. Patel, N.S. Maloney, T.-C. Liu, A.C.Y. Ng, C.E. Storer, R.D. Head, 
R. Xavier, T.S. Stappenbeck, and H.W. Virgin. 2010. Virus-plus-suscepti-
bility gene interaction determines Crohn’s disease gene Atg16L1 pheno-
types in intestine. Cell. 141:1135–1145. https:// doi .org/ 10 .1016/ j .cell .2010 
.05 .009
Cerboni, S., N. Jeremiah, M. Gentili, U. Gehrmann, C. Conrad, M.-C. Stolzen-
berg, C. Picard, B. Neven, A. Fischer, S. Amigorena, et al. 2017. Intrinsic 
antiproliferative activity of the innate sensor STI NG in T lymphocytes. 
J. Exp. Med. 214:1769–1785. https:// doi .org/ 10 .1084/ jem .20161674
Chen, H., and P.C. Boutros. 2011. VennDiagram: a package for the generation of 
highly-customizable Venn and Euler diagrams in R. BMC Bioinformatics. 
12:35. https:// doi .org/ 10 .1186/ 1471 -2105 -12 -35
Chiriac, M.T., B. Buchen, A. Wandersee, G. Hundorfean, C. Günther, Y. Bourjau, 
S.E. Doyle, B. Frey, A.B. Ekici, C. Büttner, et al. 2017. Activation of Epithe-
lial Signal Transducer and Activator of Transcription 1 by Interleukin 
28 Controls Mucosal Healing in Mice With Colitis and Is Increased in 
Mucosa of Patients With Inflammatory Bowel Disease. Gastroenterology. 
153:123–138.e8. https:// doi .org/ 10 .1053/ j .gastro .2017 .03 .015
Dannappel, M., K. Vlantis, S. Kumari, A. Polykratis, C. Kim, L. Wachsmuth, 
C. Eftychi, J. Lin, T. Corona, N. Hermance, et al. 2014. RIPK1 maintains 
epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature. 
513:90–94. https:// doi .org/ 10 .1038/ nature13608
Deuring, J.J., G.M. Fuhler, S.R. Konstantinov, M.P. Peppelenbosch, E.J. Kui-
pers, C. de Haar, and C.J. van der Woude. 2014. Genomic ATG16L1 risk 
allele-restricted Paneth cell ER stress in quiescent Crohn’s disease. Gut. 
63:1081–1091. https:// doi .org/ 10 .1136/ gutjnl -2012 -303527
Duprez, L., N. Takahashi, F. Van Hauwermeiren, B. Vandendriessche, V. Goos-
sens, T. Vanden Berghe, W. Declercq, C. Libert, A. Cauwels, and P. Van-
denabeele. 2011. RIP kinase-dependent necrosis drives lethal systemic 
inflammatory response syndrome. Immunity. 35:908–918. https:// doi 
.org/ 10 .1016/ j .immuni .2011 .09 .020
Durães, C., J.C. Machado, F. Portela, S. Rodrigues, P. Lago, M. Cravo, P. Ministro, 
M. Marques, I. Cremers, J. Freitas, et al. 2013. Phenotype-genotype pro-
files in Crohn’s disease predicted by genetic markers in autophagy-re-
lated genes (GOIA study II). Inflamm. Bowel Dis. 19:230–239. https:// doi 
.org/ 10 .1002/ ibd .23007
Feagan, B.G., W.J. Sandborn, G. D’Haens, J. Panés, A. Kaser, M. Ferrante, E. 
Louis, D. Franchimont, O. Dewit, U. Seidler, et al. 2017. Induction ther-
apy with the selective interleukin-23 inhibitor risankizumab in patients 
with moderate-to-severe Crohn’s disease: a randomised, double-blind, 
placebo-controlled phase 2 study. Lancet. 389:1699–1709. https:// doi 
.org/ 10 .1016/ S0140 -6736(17)30570 -6
Franke, A., D.P.B. McGovern, J.C. Barrett, K. Wang, G.L. Radford-Smith, 
T. Ahmad, C.W. Lees, T. Balschun, J. Lee, R. Roberts, et al. 2010. Ge-
nome-wide meta-analysis increases to 71 the number of confirmed 
Crohn’s disease susceptibility loci. Nat. Genet. 42:1118–1125. https:// doi 
.org/ 10 .1038/ ng .717
Gaidt, M.M., T.S. Ebert, D. Chauhan, K. Ramshorn, F. Pinci, S. Zuber, F. O’Duill, 
J.L. Schmid-Burgk, F. Hoss, R. Buhmann, et al. 2017. The DNA Inflam-
masome in Human Myeloid Cells Is Initiated by a STI NG-Cell Death 
Program Upstream of NLRP3. Cell. 171:1110–1124.e18. https:// doi .org/ 10 
.1016/ j .cell .2017 .09 .039
Geremia, A., C.V. Arancibia-Cárcamo, M.P.P. Fleming, N. Rust, B. Singh, N.J. 
Mortensen, S.P.L. Travis, and F. Powrie. 2011. IL-23-responsive innate 
lymphoid cells are increased in inflammatory bowel disease. J. Exp. Med. 
208:1127–1133. https:// doi .org/ 10 .1084/ jem .20101712
Günther, C., E. Martini, N. Wittkopf, K. Amann, B. Weigmann, H. Neumann, 
M.J. Waldner, S.M. Hedrick, S. Tenzer, M.F. Neurath, and C. Becker. 2011. 
Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal 
ileitis. Nature. 477:335–339. https:// doi .org/ 10 .1038/ nature10400
Günther, C., G.-W. He, A.E. Kremer, J.M. Murphy, E.J. Petrie, K. Amann, P. 
Vandenabeele, A. Linkermann, C. Poremba, U. Schleicher, et al. 2016. 
The pseudokinase MLKL mediates programmed hepatocellular necrosis 
independently of RIPK3 during hepatitis. J. Clin. Invest. 126:4346–4360. 
https:// doi .org/ 10 .1172/ JCI87545
Hampe, J., A. Franke, P. Rosenstiel, A. Till, M. Teuber, K. Huse, M. Albrecht, 
G. Mayr, F.M. De La Vega, J. Briggs, et al. 2007. A genome-wide associ-
ation scan of nonsynonymous SNPs identifies a susceptibility variant 
for Crohn disease in ATG16L1. Nat. Genet. 39:207–211. https:// doi .org/ 
10 .1038/ ng1954
Hasnain, S.Z., S. Tauro, I. Das, H. Tong, A.C.H. Chen, P.L. Jeffery, V. McDonald, 
T.H. Florin, and M.A. McGuckin. 2013. IL-10 promotes production of 
intestinal mucus by suppressing protein misfolding and endoplasmic 
Aden et al. 
ATG16L1 licenses protective IL-22 signaling
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20171029
18
reticulum stress in goblet cells. Gastroenterology. 144:357–368.e9. https:// 
doi .org/ 10 .1053/ j .gastro .2012 .10 .043
Hasnain, S.Z., D.J. Borg, B.E. Harcourt, H. Tong, Y.H. Sheng, C.P. Ng, I. Das, 
R. Wang, A.C.H. Chen, T. Loudovaris, et al. 2014. Glycemic control in 
diabetes is restored by therapeutic manipulation of cytokines that reg-
ulate beta cell stress. Nat. Med. 20:1417–1426. https:// doi .org/ 10 .1038/ 
nm .3705
Hernández, P.P., T. Mahlakoiv, I. Yang, V. Schwierzeck, N. Nguyen, F. Guendel, 
K. Gronke, B. Ryffel, C. Hoelscher, L. Dumoutier, et al. 2015. Interfer-
on-λ and interleukin 22 act synergistically for the induction of inter-
feron-stimulated genes and control of rotavirus infection. Nat. Immunol. 
16:698–707. https:// doi .org/ 10 .1038/ ni .3180
Huber, S., N. Gagliani, L.A. Zenewicz, F.J. Huber, L. Bosurgi, B. Hu, M. Hedl, 
W. Zhang, W. O’Connor Jr., A.J. Murphy, et al. 2012. IL-22BP is regulated 
by the inflammasome and modulates tumorigenesis in the intestine. 
Nature. 491:259–263. https:// doi .org/ 10 .1038/ nature11535
Jostins, L., S. Ripke, R.K. Weersma, R.H. Duerr, D.P. McGovern, K.Y. Hui, J.C. 
Lee, L.P. Schumm, Y. Sharma, C.A. Anderson, et al. International IBD 
Genetics Consortium (IIB DGC). 2012. Host-microbe interactions have 
shaped the genetic architecture of inflammatory bowel disease. Nature. 
491:119–124. https:// doi .org/ 10 .1038/ nature11582
Kaser, A., A.-H. Lee, A. Franke, J.N. Glickman, S. Zeissig, H. Tilg, E.E.S. Nieu-
wenhuis, D.E. Higgins, S. Schreiber, L.H. Glimcher, and R.S. Blumberg. 
2008. XBP1 links ER stress to intestinal inflammation and confers ge-
netic risk for human inflammatory bowel disease. Cell. 134:743–756. 
https:// doi .org/ 10 .1016/ j .cell .2008 .07 .021
Kuriakose, T., S.M. Man, R.K.S. Malireddi, R. Karki, S. Kesavardhana, D.E. 
Place, G. Neale, P. Vogel, and T.-D. Kanneganti. 2016. ZBP1/DAI is an in-
nate sensor of influenza virus triggering the NLRP3 inflammasome and 
programmed cell death pathways. Sci. Immunol. 1:aag2045. https:// doi 
.org/ 10 .1126/ sciimmunol .aag2045
Larkin, B., V. Ilyukha, M. Sorokin, A. Buzdin, E. Vannier, and A. Poltorak. 
2017. Cutting Edge: Activation of STI NG in T Cells Induces Type I IFN 
Responses and Cell Death. J. Immunol. 199:397–402. https:// doi .org/ 10 
.4049/ jimmunol .1601999
Lassen, K.G., P. Kuballa, K.L. Conway, K.K. Patel, C.E. Becker, J.M. Peloquin, 
E.J. Villablanca, J.M. Norman, T.-C. Liu, R.J. Heath, et al. 2014. Atg16L1 
T300A variant decreases selective autophagy resulting in altered cyto-
kine signaling and decreased antibacterial defense. Proc. Natl. Acad. Sci. 
USA. 111:7741–7746. https:// doi .org/ 10 .1073/ pnas .1407001111
Legarda, D., S.J. Justus, R.L. Ang, N. Rikhi, W. Li, T.M. Moran, J. Zhang, E. 
Mizoguchi, M. Zelic, M.A. Kelliher, et al. 2016. CYLD Proteolysis Pro-
tects Macrophages from TNF-Mediated Auto-necroptosis Induced by 
LPS and Licensed by Type I IFN. Cell Reports. 15:2449–2461. https:// doi 
.org/ 10 .1016/ j .celrep .2016 .05 .032
Lekkerkerker, A., B. Harder, P. Kulkarni, R. Zhao, M. Choi, A. Noyes, A. Po-
lihrom, D. Fillos, J. Rae, D. Danilenko, et al. 2017. P418 Pharmacodynamic 
biomarkers demonstrate dose-dependent pharmacological activity of 
the IL-22Fc fusion protein UTR1147A in healthy volunteers in a phase 1a 
clinical trial. J. Crohn’s Colitis. 11(suppl_1):S289. https:// doi .org/ 10 .1093/ 
ecco -jcc/ jjx002 .543
Liang, C.C., A.Y. Park, and J.L. Guan. 2007. In vitro scratch assay: a convenient 
and inexpensive method for analysis of cell migration in vitro. Nat. Pro-
toc. 2:329–333. https:// doi .org/ 10 .1038/ nprot .2007 .30
Lindemans, C.A., M. Calafiore, A.M. Mertelsmann, M.H. O’Connor, J.A. Du-
dakov, R.R. Jenq, E. Velardi, L.F. Young, O.M. Smith, G. Lawrence, et 
al. 2015. Interleukin-22 promotes intestinal-stem-cell-mediated ep-
ithelial regeneration. Nature. 528:560–564. https:// doi .org/ 10 .1038/ 
nature16460
Liu, E.Y., N. Xu, J. O’Prey, L.Y. Lao, S. Joshi, J.S. Long, M. O’Prey, D.R. Croft, F. 
Beaumatin, A.D. Baudot, et al. 2015. Loss of autophagy causes a synthetic 
lethal deficiency in DNA repair. Proc. Natl. Acad. Sci. USA. 112:773–778. 
https:// doi .org/ 10 .1073/ pnas .1409563112
Love, M.I., W. Huber, and S. Anders. 2014. Moderated estimation of fold 
change and dispersion for RNA-seq data with DESeq2. Genome Biol. 
15:550. https:// doi .org/ 10 .1186/ s13059 -014 -0550 -8
Lübbers, J., M. Brink, L.A. van de Stadt, S. Vosslamber, J.G. Wesseling, D. van 
Schaardenburg, S. Rantapää-Dahlqvist, and C.L. Verweij. 2013. The 
type I IFN signature as a biomarker of preclinical rheumatoid arthritis. 
Ann. Rheum. Dis. 72:776–780. https:// doi .org/ 10 .1136/ annrheumdis -2012 
-202753
Martin, M. 2011. Cutadapt removes adapter sequences from high-through-
put sequencing reads. 2011. EMBnet.journal. 17:10–12. https:// doi .org/ 10 
.14806/ ej .17 .1 .200
Matsuzawa-Ishimoto, Y., Y. Shono, L.E. Gomez, V.M. Hubbard-Lucey, M. Cam-
mer, J. Neil, M.Z. Dewan, S.R. Lieberman, A. Lazrak, J.M. Marinis, et al. 
2017. Autophagy protein ATG16L1 prevents necroptosis in the intesti-
nal epithelium. J. Exp. Med. 214:3687–3705. https:// doi .org/ 10 .1084/ jem 
.20170558
McGovern, D.P.B., A. Gardet, L. Törkvist, P. Goyette, J. Essers, K.D. Taylor, B.M. 
Neale, R.T.H. Ong, C. Lagacé, C. Li, et al. NID DK IBD Genetics Consor-
tium. 2010. Genome-wide association identifies multiple ulcerative coli-
tis susceptibility loci. Nat. Genet. 42:332–337. https:// doi .org/ 10 .1038/ ng 
.549
Mielke, L.A., S.A. Jones, M. Raverdeau, R. Higgs, A. Stefanska, J.R. Groom, A. 
Misiak, L.S. Dungan, C.E. Sutton, G. Streubel, et al. 2013. Retinoic acid 
expression associates with enhanced IL-22 production by γδ T cells and 
innate lymphoid cells and attenuation of intestinal inflammation. J. Exp. 
Med. 210:1117–1124. https:// doi .org/ 10 .1084/ jem .20121588
Mouna, L., E. Hernandez, D. Bonte, R. Brost, L. Amazit, L.R. Delgui, W. Brune, 
A.P. Geballe, I. Beau, and A. Esclatine. 2016. Analysis of the role of au-
tophagy inhibition by two complementary human cytomegalovirus 
BECN1/Beclin 1-binding proteins. Autophagy. 12:327–342. https:// doi 
.org/ 10 .1080/ 15548627 .2015 .1125071
Niederreiter, L., T.M.J. Fritz, T.E. Adolph, A.-M. Krismer, F.A. Offner, M. 
Tschurtschenthaler, M.B. Flak, S. Hosomi, M.F. Tomczak, N.C. Kaneider, 
et al. 2013. ER stress transcription factor Xbp1 suppresses intestinal tu-
morigenesis and directs intestinal stem cells. J. Exp. Med. 210:2041–2056. 
https:// doi .org/ 10 .1084/ jem .20122341
Nikolaus, S., B. Schulte, N. Al-Massad, F. Thieme, D.M. Schulte, J. Bethge, 
A. Rehman, F. Tran, K. Aden, R. Häsler, et al. 2017. Increased Trypto-
phan Metabolism Is Associated With Activity of Inflammatory Bowel 
Diseases. Gastroenterology. 153:1504–1516.e2. https:// doi .org/ 10 .1053/ j 
.gastro .2017 .08 .028
Pelczar, P., M. Witkowski, L.G. Perez, J. Kempski, A.G. Hammel, L. Brockmann, 
D. Kleinschmidt, S. Wende, C. Haueis, T. Bedke, et al. 2016. A pathogenic 
role for T cell-derived IL-22BP in inflammatory bowel disease. Science. 
354:358–362. https:// doi .org/ 10 .1126/ science .aah5903
Pham, T.A.N., S. Clare, D. Goulding, J.M. Arasteh, M.D. Stares, H.P. Browne, 
J.A. Keane, A.J. Page, N. Kumasaka, L. Kane, et al. Sanger Mouse Genetics 
Project. 2014. Epithelial IL-22RA1-mediated fucosylation promotes in-
testinal colonization resistance to an opportunistic pathogen. Cell Host 
Microbe. 16:504–516. https:// doi .org/ 10 .1016/ j .chom .2014 .08 .017
Pickert, G., C. Neufert, M. Leppkes, Y. Zheng, N. Wittkopf, M. Warntjen, H.-A. 
Lehr, S. Hirth, B. Weigmann, S. Wirtz, et al. 2009. STAT3 links IL-22 
signaling in intestinal epithelial cells to mucosal wound healing. J. Exp. 
Med. 206:1465–1472. https:// doi .org/ 10 .1084/ jem .20082683
Prabakaran, T., C. Bodda, C. Krapp, B.C. Zhang, M.H. Christensen, C. Sun, L. 
Reinert, Y. Cai, S.B. Jensen, M.K. Skouboe, et al. 2018. Attenuation of 
cGAS-STI NG signaling is mediated by a p62/SQS TM1-dependent auto-
phagy pathway activated by TBK1. EMBO J. 37:e97858. https:// doi .org/ 
10 .15252/ embj .201797858
Qiang, L., B. Zhao, P. Shah, A. Sample, S. Yang, and Y.-Y. He. 2016. Autophagy 
positively regulates DNA damage recognition by nucleotide excision 
repair. Autophagy. 12:357–368. https:// doi .org/ 10 .1080/ 15548627 .2015 
.1110667
Sabat, R., W. Ouyang, and K. Wolk. 2014. Therapeutic opportunities of the 
IL-22-IL-22R1 system. Nat. Rev. Drug Discov. 13:21–38. https:// doi .org/ 10 
.1038/ nrd4176
Saitoh, T., N. Fujita, T. Hayashi, K. Takahara, T. Satoh, H. Lee, K. Matsunaga, S. 
Kageyama, H. Omori, T. Noda, et al. 2009. Atg9a controls dsDNA-driven 
dynamic translocation of STI NG and the innate immune response. Proc. 
Natl. Acad. Sci. USA. 106:20842–20846. https:// doi .org/ 10 .1073/ pnas 
.0911267106
Sato, T., R.G. Vries, H.J. Snippert, M. van de Wetering, N. Barker, D.E. Stange, 
J.H. van Es, A. Abo, P. Kujala, P.J. Peters, and H. Clevers. 2009. Single Lgr5 
stem cells build crypt-villus structures in vitro without a mesenchymal 
niche. Nature. 459:262–265. https:// doi .org/ 10 .1038/ nature07935
Sauer, J.-D., K. Sotelo-Troha, J. von Moltke, K.M. Monroe, C.S. Rae, S.W. Bru-
baker, M. Hyodo, Y. Hayakawa, J.J. Woodward, D.A. Portnoy, and R.E. 
Vance. 2011. The N-ethyl-N-nitrosourea-induced Goldenticket mouse 
mutant reveals an essential function of Sting in the in vivo interferon 
response to Listeria monocytogenes and cyclic dinucleotides. Infect. 
Immun. 79:688–694. https:// doi .org/ 10 .1128/ IAI .00999 -10
Aden et al. 
ATG16L1 licenses protective IL-22 signaling
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20171029
19
Schneider, W.M., M.D. Chevillotte, and C.M. Rice. 2014. Interferon-stimulated 
genes: a complex web of host defenses. Annu. Rev. Immunol. 32:513–545. 
https:// doi .org/ 10 .1146/ annurev -immunol -032713 -120231
Siegmund, B., H.-A. Lehr, G. Fantuzzi, and C.A. Dinarello. 2001. IL-1 β -con-
verting enzyme (caspase-1) in intestinal inflammation. Proc. Natl. Acad. 
Sci. USA. 98:13249–13254. https:// doi .org/ 10 .1073/ pnas .231473998
Sonnenberg, G.F., L.A. Fouser, and D. Artis. 2011. Border patrol: regulation 
of immunity, inflammation and tissue homeostasis at barrier sur-
faces by IL-22. Nat. Immunol. 12:383–390. https:// doi .org/ 10 .1038/ 
ni .2025
Stefanich, E.G., J. Rae, S. Sukumaran, J. Lutman, A. Lekkerkerker, W. Ouy-
ang, X. Wang, D. Lee, D.M. Danilenko, L. Diehl, et al. 2018. Pre-clin-
ical and translational pharmacology of a human interleukin-22 IgG 
fusion protein for potential treatment of infectious or inflammatory 
diseases. Biochem. Pharmacol. 152:224–235. https:// doi .org/ 10 .1016/ j 
.bcp .2018 .03 .031
Sze, A., S.M. Belgnaoui, D. Olagnier, R. Lin, J. Hiscott, and J. van Grevenyn-
ghe. 2013. Host restriction factor SAM HD1 limits human T cell leuke-
mia virus type 1 infection of monocytes via STI NG-mediated apoptosis. 
Cell Host Microbe. 14:422–434. https:// doi .org/ 10 .1016/ j .chom .2013 .09 
.009
Szklarczyk, D., A. Franceschini, S. Wyder, K. Forslund, D. Heller, J. Huerta-Ce-
pas, M. Simonovic, A. Roth, A. Santos, K.P. Tsafou, et al. 2015. STR ING 
v10: protein-protein interaction networks, integrated over the tree of 
life. Nucleic Acids Res. 43(Database issue, D1):D447–D452. https:// doi .org/ 
10 .1093/ nar/ gku1003
Trapnell, C., A. Roberts, L. Goff, G. Pertea, D. Kim, D.R. Kelley, H. Pimentel, S.L. 
Salzberg, J.L. Rinn, and L. Pachter. 2012. Differential gene and transcript 
expression analysis of RNA-seq experiments with TopHat and Cufflinks. 
Nat. Protoc. 7:562–578. https:// doi .org/ 10 .1038/ nprot .2012 .016
Tschurtschenthaler, M., T.E. Adolph, J.W. Ashcroft, L. Niederreiter, R. Bharti, S. 
Saveljeva, J. Bhattacharyya, M.B. Flak, D.Q. Shih, G.M. Fuhler, et al. 2017. 
Defective ATG16L1-mediated removal of IRE1α drives Crohn’s disease-like 
ileitis. J. Exp. Med. 214:401–422. https:// doi .org/ 10 .1084/ jem .20160791
Untergasser, A., I. Cutcutache, T. Koressaar, J. Ye, B.C. Faircloth, M. Remm, and 
S.G. Rozen. 2012. Primer3--new capabilities and interfaces. Nucleic Acids 
Res. 40:e115. https:// doi .org/ 10 .1093/ nar/ gks596
Wang, C., G. Gong, A. Sheh, S. Muthupalani, E.M. Bryant, D.A. Puglisi, H. 
Holcombe, E.A. Conaway, N.A.P. Parry, V. Bakthavatchalu, et al. 2017. 
Interleukin-22 drives nitric oxide-dependent DNA damage and dys-
plasia in a murine model of colitis-associated cancer. Mucosal Immunol. 
10:1504–1517. https:// doi .org/ 10 .1038/ mi .2017 .9
Welz, P.-S., A. Wullaert, K. Vlantis, V. Kondylis, V. Fernández-Majada, M. 
Ermolaeva, P. Kirsch, A. Sterner-Kock, G. van Loo, and M. Pasparakis. 
2011. FADD prevents RIP3-mediated epithelial cell necrosis and chronic 
intestinal inflammation. Nature. 477:330–334. https:// doi .org/ 10 .1038/ 
nature10273
Wu, B., A. Peisley, C. Richards, H. Yao, X. Zeng, C. Lin, F. Chu, T. Walz, and S. 
Hur. 2013. Structural basis for dsRNA recognition, filament formation, 
and antiviral signal activation by MDA5. Cell. 152:276–289. https:// doi 
.org/ 10 .1016/ j .cell .2012 .11 .048
Yang, H., T. Yamazaki, F. Pietrocola, H. Zhou, L. Zitvogel, Y. Ma, and G. Kro-
emer. 2015. STAT3 Inhibition Enhances the Therapeutic Efficacy of Im-
munogenic Chemotherapy by Stimulating Type 1 Interferon Production 
by Cancer Cells. Cancer Res. 75:3812–3822. https:// doi .org/ 10 .1158/ 0008 
-5472 .CAN -15 -1122
Zheng, Y., D.M. Danilenko, P. Valdez, I. Kasman, J. Eastham-Anderson, J. Wu, 
and W. Ouyang. 2007. Interleukin-22, a T(H)17 cytokine, mediates IL-
23-induced dermal inflammation and acanthosis. Nature. 445:648–651. 
https:// doi .org/ 10 .1038/ nature05505
Zheng, Y., P.A. Valdez, D.M. Danilenko, Y. Hu, S.M. Sa, Q. Gong, A.R. Abbas, Z. 
Modrusan, N. Ghilardi, F.J. de Sauvage, and W. Ouyang. 2008. Interleu-
kin-22 mediates early host defense against attaching and effacing bac-
terial pathogens. Nat. Med. 14:282–289. https:// doi .org/ 10 .1038/ nm1720
Zindl, C.L., J.-F. Lai, Y.K. Lee, C.L. Maynard, S.N. Harbour, W. Ouyang, D.D. 
Chaplin, and C.T. Weaver. 2013. IL-22-producing neutrophils contribute 
to antimicrobial defense and restitution of colonic epithelial integrity 
during colitis. Proc. Natl. Acad. Sci. USA. 110:12768–12773. https:// doi .org/ 
10 .1073/ pnas .1300318110
